BB-031 not checked

Basking Biosciences, Inc. · DTRI-031

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Acute Ischemic Stroke
Main trialPhase 2
“The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset. Participants will be randomized to receive one dose of either the investigational drug or placebo and will be followed for 90 days. A total of 228 patients are planned in this study.”In the company’s words, NCT06226805 on ClinicalTrials.gov
Other names
DTRI-031

Other drugs for Acute Ischemic Stroke

All 45 drugs for Acute Ischemic Stroke

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Jun 2027 Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
Phase 1Completed 19 Apr 2022 Study of DTRI-031 in Healthy Volunteers
Phase 1Completed 18 Mar 2026 Study of BB-025, Alone and After BB-031, in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow BB-031

Following is part of Solo: you see every change to BB-031 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in